BCPC Balchem (BCPC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0000009326
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
188
13F, latest reported quarter
What the filings say about BCPC
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-17
Balchem insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for BALCHEM CORP in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 31, 2024.
- The trade is 37.8% of the 11,211 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and GM, Specialty Products van Gunsteren Job Leonard sold about $648.3K of BCPC on Dec 4, 2025; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 31, 2024.
- The trade is 18.7% of the 9,446 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and GM, Specialty Products van Gunsteren Job Leonard sold about $271.5K of BCPC on Dec 4, 2025; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 8, 2024.
- The trade is 25.0% of the 7,989 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fischer David B sold about $308.3K of BCPC on Dec 3, 2025, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 8, 2024.
- The trade is 60.1% of the 9,989 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fischer David B sold about $923.5K of BCPC on Dec 3, 2025, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.2% of the 7,391 shares held after it.
- 2 other insiders sold within 30 days.
- 188 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Chief Supply Chain Officer Reid Martin Luther sold about $185.3K of BCPC on Nov 11, 2025, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 188 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
188 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+8.8% year over year
more than 58% of Pharma & Biotech
Margin
14.9% net margin
more than 85% of Pharma & Biotech
Buybacks
$71.9M repurchased, FY to 2026-09-30
more than 62% of Pharma & Biotech
Short interest
1.6% of the float short (float per yahoo 2026-10-26) · 2.1 days to cover · settled 2026-09-30
below 68% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 25 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch BCPC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BCPC: institutional holders (13F)
13F holdings, latest reported quarter
4,964,479 sh
$838.7M
2,221,267 sh
$375.3M
1,445,369 sh
$244.2M
1,281,552 sh
$216.5M
1,122,146 sh
$189.6M
Congress trades in BCPC
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-17 · disclosed 25 days later
$1,001 - $15,000
Bought 2026-07-10 · disclosed 56 days later
$1,001 - $15,000
Sold 2025-04-09 · disclosed 35 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BCPC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BCPC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Materials ETF
$1.3M position · as of 2026-05-31
6.4%
CONESTOGA SMALL CAP FUND
$86.0M position · as of 2026-06-30
4.2%
CONESTOGA SMID CAP FUND
$19.4M position · as of 2026-06-30
4.1%
GMO Small Cap Quality Fund
$25.2M position · as of 2026-05-31
3.6%
Geneva SMID Cap Growth Fund
$1.6M position · as of 2026-05-31
3.6%
Nationwide Geneva Small Cap Growth Fund
$27.4M position · as of 2026-07-31
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Ted Harris
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$5.9M
$10.9M
$1.3M
+49%
+25%
2022
$11.9M
$8.0M
$1.2M
+22%
+23%
2021
$5.8M
$12.2M
$1.3M
+67%
+43%
2020
$4.6M
$5.6M
$1.0M
+14%
+15%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 188 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
BCPC financials
Revenue growth
+8.8%
XBRL, annual
Net margin
14.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM BCPC
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $953.7M |
| FY Dec 2023 | $922.4M |
| FY Dec 2022 | $942.4M |
| FY Dec 2021 | $799.0M |
| Sep 2026 | $290.7M |
| Jun 2026 | $284.0M |
| Mar 2026 | $270.7M |
| Dec 2025 | $263.6M |
| Sep 2025 | $267.6M |
| Jun 2025 | $255.5M |
| Mar 2025 | $250.5M |
| Dec 2024 | $240.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.4%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM BCPC
| FY Dec 2025 | +14.9% |
| FY Dec 2024 | +13.5% |
| FY Dec 2023 | +11.8% |
| FY Dec 2022 | +11.2% |
| FY Dec 2021 | +12.0% |
| Sep 2026 | +16.1% |
| Jun 2026 | +15.7% |
| Mar 2026 | +14.9% |
| Dec 2025 | +14.9% |
| Sep 2025 | +15.1% |
| Jun 2025 | +15.0% |
| Mar 2025 | +14.8% |
| Dec 2024 | +14.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$178.0M
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM BCPC
| FY Dec 2025 | $173.1M |
| FY Dec 2024 | $146.3M |
| FY Dec 2023 | $145.9M |
| FY Dec 2022 | $89.5M |
| FY Dec 2021 | $124.4M |
| Sep 2026 | $57.3M |
| Jun 2026 | $35.8M |
| Mar 2026 | $33.8M |
| Dec 2025 | $51.1M |
| Sep 2025 | $50.7M |
| Jun 2025 | $40.4M |
| Mar 2025 | $30.9M |
| Dec 2024 | $39.6M |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2026-09-30 plus current 2019-12-31 (82 months older than the period end); equity 2026-09-30
Debt to equity BCPC
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.03x |
| FY Dec 2021 | 0.02x |
| Sep 2026 | 0.02x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
9.17x
TTM operating cash flow over long-term 2026-09-30 plus current 2019-12-31 (82 months older than the period end)
Cash flow to debt BCPC
| FY Dec 2025 | 9.05x |
| FY Dec 2024 | 8.34x |
| FY Dec 2023 | 9.65x |
| FY Dec 2022 | 4.73x |
| FY Dec 2021 | 9.92x |
| Sep 2026 | 9.17x |
| Jun 2026 | 8.76x |
| Mar 2026 | 9.13x |
| Dec 2025 | 9.05x |
| Sep 2025 | 8.46x |
| Jun 2025 | 8.11x |
| Mar 2025 | 8.26x |
| Dec 2024 | 8.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+13.0%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity BCPC
| FY Dec 2025 | +12.9% |
| FY Dec 2024 | +11.7% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +11.6% |
| FY Dec 2021 | +11.3% |
| Sep 2026 | +13.0% |
| Jun 2026 | +12.8% |
| Mar 2026 | +12.7% |
| Dec 2025 | +12.9% |
| Sep 2025 | +12.1% |
| Jun 2025 | +12.0% |
| Mar 2025 | +11.9% |
| Dec 2024 | +11.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.2%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets BCPC
| FY Dec 2025 | +9.5% |
| FY Dec 2024 | +8.1% |
| FY Dec 2023 | +6.7% |
| FY Dec 2022 | +7.5% |
| FY Dec 2021 | +8.1% |
| Sep 2026 | +10.2% |
| Jun 2026 | +9.8% |
| Mar 2026 | +9.5% |
| Dec 2025 | +9.5% |
| Sep 2025 | +9.2% |
| Jun 2025 | +8.8% |
| Mar 2025 | +8.5% |
| Dec 2024 | +8.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+14.0%
operating income after a 22.5% effective tax rate, over long-term 2026-09-30 plus current 2019-12-31 (82 months older than the period end) plus average of 2025-09-30 and 2026-09-30 minus cash
Return on invested capital BCPC
| FY Dec 2025 | +14.0% |
| FY Dec 2024 | +13.2% |
| FY Dec 2023 | +13.3% |
| FY Dec 2022 | +13.4% |
| FY Dec 2021 | +12.6% |
| Sep 2026 | +14.0% |
| Jun 2026 | +13.8% |
| Mar 2026 | +13.7% |
| Dec 2025 | +14.0% |
| Sep 2025 | +13.2% |
| Jun 2025 | +13.3% |
| Mar 2025 | +13.3% |
| Dec 2024 | +13.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.9%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed BCPC
| FY Dec 2025 | +14.3% |
| FY Dec 2024 | +12.8% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +11.4% |
| FY Dec 2021 | +12.0% |
| Sep 2026 | +14.9% |
| Jun 2026 | +14.4% |
| Mar 2026 | +14.2% |
| Dec 2025 | +14.3% |
| Sep 2025 | +13.5% |
| Jun 2025 | +13.2% |
| Mar 2025 | +13.1% |
| Dec 2024 | +12.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
32.13x
close 2026-10-26 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing BCPC
| FY Dec 2025 | 32.29x |
| FY Dec 2024 | 41.48x |
| FY Dec 2023 | 44.40x |
| FY Dec 2022 | 37.57x |
| FY Dec 2021 | 57.15x |
| Sep 2026 | 31.07x |
| Jun 2026 | 33.19x |
| Mar 2026 | 34.80x |
| Dec 2025 | 32.29x |
| Sep 2025 | 32.84x |
| Jun 2025 | 36.51x |
| Mar 2025 | 39.81x |
| Dec 2024 | 41.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.4B
market value at close 2026-10-26 on 2026-10-15 shares, plus long-term 2026-09-30 plus current 2019-12-31 (82 months older than the period end), minus cash 2026-09-30
Enterprise value BCPC
| FY Dec 2025 | $4.9B |
| FY Dec 2024 | $5.3B |
| FY Dec 2023 | $4.8B |
| FY Dec 2022 | $3.9B |
| FY Dec 2021 | $5.4B |
| Sep 2026 | $5.2B |
| Jun 2026 | $5.4B |
| Mar 2026 | $5.4B |
| Dec 2025 | $4.9B |
| Sep 2025 | $4.8B |
| Jun 2025 | $5.2B |
| Mar 2025 | $5.4B |
| Dec 2024 | $5.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield BCPC
| FY Dec 2025 | +3.5% |
| FY Dec 2024 | +2.8% |
| FY Dec 2023 | +3.0% |
| FY Dec 2022 | +2.3% |
| FY Dec 2021 | +2.3% |
| Sep 2026 | +3.4% |
| Jun 2026 | +3.2% |
| Mar 2026 | +3.2% |
| Dec 2025 | +3.5% |
| Sep 2025 | +3.3% |
| Jun 2025 | +2.9% |
| Mar 2025 | +2.8% |
| Dec 2024 | +2.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.98x
P/E over trailing EPS growth of 16%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing BCPC
| FY Dec 2025 | 1.55x |
| FY Dec 2024 | 2.40x |
| FY Dec 2023 | 14.43x |
| FY Dec 2022 | 3.69x |
| FY Dec 2021 | 4.25x |
| Sep 2026 | 1.92x |
| Jun 2026 | 1.98x |
| Mar 2026 | 2.07x |
| Dec 2025 | 1.55x |
| Sep 2025 | 1.44x |
| Jun 2025 | 1.70x |
| Mar 2025 | 2.24x |
| Dec 2024 | 2.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.0B | $953.7M | $922.4M | $942.4M |
| Gross profit | $370.6M | $336.2M | $302.1M | $280.5M |
| Operating income | $209.3M | $182.9M | $159.2M | $145.2M |
| Net income | $154.8M | $128.5M | $108.5M | $105.4M |
| EPS (diluted) | 4.75 | 3.93 | 3.35 | 3.25 |
| Operating cash flow | $216.6M | $182.0M | $183.8M | $138.5M |
| Cash | $74.6M | $49.5M | $64.4M | $66.6M |
| Long-term debt | $21.4M | $19.3M | $16.6M | $26.8M |
| Buybacks | $107.6M | $5.7M | $4.5M | $35.4M |
| Dividends paid | $28.3M | $25.6M | $22.9M | $20.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
BCPC Stock Sonar score 5/7 axes
Find similar shapesCompareBCPC ranks highest on financial health (84th percentile) and profitability (78th), and lowest on risk and compliance (52nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BCPC filings, in plain words
Have members of Congress traded BCPC?
Yes. In the year to 2026-10-27, 1 House member disclosed buying BCPC and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-17.
Read the full summary
In the year to 2026-10-27, 1 member of Congress disclosed buying BCPC and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-17. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
